EGFR and non-small cell lung carcinoma: Osimertinib, also known as AZD9291, is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) approved for the treatment of patients with non-small cell lung cancer (NSCLC) with a T790M mutation in EGFR.